Study of Urinary Angiotensinogen as a Marker to Warn the Deterioration of Renal Function in CKD Patients Early.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01118494
Recruitment Status : Unknown
Verified April 2010 by Fudan University.
Recruitment status was:  Recruiting
First Posted : May 6, 2010
Last Update Posted : May 6, 2010
Information provided by:
Fudan University

April 26, 2010
May 6, 2010
May 6, 2010
September 2009
February 2010   (Final data collection date for primary outcome measure)
Urinary AGT level [ Time Frame: 12 months ]
Urinary AGT level can be an early bio-marker of intrarenal RAS activation and prewarning the deterioration of renal function.
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
Study of Urinary Angiotensinogen as a Marker to Warn the Deterioration of Renal Function in CKD Patients Early.
Not Provided
Chronic kidney disease (CKD) that results in end-stage renal disease (ESRD) is a major international health problem. Many clinical markers such as urine protein or eGFR(evaluated glomerular filtration rate),can estimate the renal function, but not sensitive. As well-known, the crucial role of angiotensin II (AngII), the major effector of the renin-angiotensin system (RAS), in the development of renal fibrosis that results in ESRD is widely recognized.Abundant researches find that intrarenal RAS takes an important role on the progression of CKD. At present, no clinical marker is available to evaluate intrarenal AngII activity because it is difficult to measure it directly in patients. So find and establish a bio-marker of local renal RAS activation maybe a breakthrough in early detection and treatment of CKD. Angiotensinogen(AGT) is the only known substrate for renin and the level of AGT in humans is close to Km value for renin. Thus , changes in AGT levels can control the activity of the RAS, and its up-regulation may lead to activity of Ang levels. Then we hypothesis that the AGT is a early bio-marker of local renal RAS activation as well as CKD.
  1. Screening: Select CKD(3-4) patients from outpatients, Urine routine examination and Renal B-mode ultrasonography and so on.
  2. Confirm: Sign consent with the patients who meet the inclusion criteria, then these patients are included in the study.
  3. Create patients records and complete related-inspections.
  4. Clinical follow-up: Follow-up once every six months, and we will record every patient's disease progress every time. Each follow-up, the patient needs to leave 5 ml blood samples and 20 ml of urine samples, used for the following study.
  5. Detection, Observation and Evaluation: Patients are divided into two groups according to AGT levels: higher than the normal group and the normal group. Observe the changes in eGFR of different group. Statistics judge whether AGT can be as a early warning indicators of renal function decline.
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Retention:   Samples With DNA
serum plasma urine supernatant urine sediment
Non-Probability Sample
CKD(chronic kidney disease),in the stage of 3 or 4.
  • Chronic Kidney Disease
  • Urinary Angiotensinogen
Not Provided
CKD patients
People who have been diagnosed with CKD,and been in the stage of 3 or 4.
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Unknown status
Same as current
June 2011
February 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • CKD, in the stage of 3 or 4, and kidney biopsy is preferred selection;
  • Signed the informed consent;

Exclusion Criteria:

  • Kidney cancer patients;
  • Kidney transplantation;
  • Hereditary kidney disease;
  • Secondary renal disease(diabetic nephropathy and hypertensive nephropathy are excluded)
Sexes Eligible for Study: All
18 Years to 80 Years   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
HuaShan Hospital of Fudan University, Nephrology Department
Fudan University
Not Provided
Not Provided
Fudan University
April 2010